维奈克拉联合传统化疗治疗儿童复发性急性早幼粒白血病1例及文献复习
徐彩婷 徐晓军通讯作者

浙江大学医学院，浙江杭州，311404；

摘要：本研究通过1例患儿探讨维奈克拉联合传统化疗在儿童复发性AML-M3中的应用，分析其疗效与安全性并进行文献复习。结果显示，维奈克拉联合传统治疗安全有效，未来需优化方案并开展更多临床研究。

关键词：维奈克拉；传统化疗；早幼粒白血病

参考文献

[1]O’Donnell M R, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology[J]. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15(7): 926-957.

[2]Shen Z X, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia[J]. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(15): 5328-5335.

[3]Pourrajab F, et al. Genetic characterization and risk stratification of acute myeloid leukemia[J]. Cancer Management and Research, 2020, Volume 12: 2231-2253.

[4]Konopleva M, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia[J]. Cancer Discovery, 2016, 6(10): 1106-1117.

[5]温晓佳, 等. 以维奈克拉为基础的诱导方案对初诊儿童急性髓细胞白血病的疗效[J]. 中华医学杂志, 2024, 104(27): 2513-2520.

[6]张文荟, 等. 高三尖杉酯碱联合阿扎胞苷与Venetoclax治疗难治/复发急性髓系白血病疗效观察[J]. 新乡医学院学报, 2021, 38(6): 580-584.

[7]Trabal A, et al. Venetoclax for acute myeloid leukemia in pediatric patients: a texas medical center experience[J]. Cancers, 2023, 15(7): 1983.

[8]Karol S E, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study[J]. Lancet Oncology, 2020, 21(4): 551-560.

[9]Marinoff A E, et al. Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies[J]. Pediatric Blood and Cancer, 2023, 70(6): e30335.

[10]Winters A C, et al. Single‐center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia[J]. Pediatric Blood and Cancer, 2020, 67(10): e28398.

[11]Masetti R, et al. Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis[J]. Blood Advances, 2023, 7(16): 4366-4370.

[12]Papaemmanuil E, et al. Genomic classification and prognosis in acute myeloid leukemia[J]. New England Journal of Medicine, 2016, 374(23): 2209-2221.